Rumeysa Fayetörbay, Network-Based Discovery of Molecular Targeted Agent Treatments in Hepatocellular Carcinoma
Sorafenib is one of FDA approved targeted agents in HCC treatment. PI3K/AKT pathway is altered in 50% of hepatoma, hence understanding how Sorafenib and PI3K/AKT pathway inhibitors act at signalling level is crucial for targeted therapies and to reveal their off-target effects. In this work, we use gene expression profiles of HCC cells treated with seven different drugs/inhibitors and combination. Our aim is to reveal the important targets and modulators in a drug treatment by inferring the dysregulation of Interactome. In other words, we search for the mechanism of action of drugs in a network context beyond gene list.
Date: 13.01.2020 / 14:00 Place: A-108









